Abstract
In Australia, 0.5–2.0% of the population are chronically infected
with the hepatitis B virus (HBV). Half of these people are immigrants born in
high-endemicity countries. Australia’s immigration patterns, the ageing of
individuals with chronic HBV infection and the low proportion receiving HBV
drug therapy together mean the long-term sequelae of HBV infection will
become increasingly evident. This study projects the mortality, morbidity and
direct costs of HBV infection in Australia to 2017, and investigates the costeffectiveness
of increasing the proportion of people with chronic hepatitis B
(CHB) receiving drug therapy.
with the hepatitis B virus (HBV). Half of these people are immigrants born in
high-endemicity countries. Australia’s immigration patterns, the ageing of
individuals with chronic HBV infection and the low proportion receiving HBV
drug therapy together mean the long-term sequelae of HBV infection will
become increasingly evident. This study projects the mortality, morbidity and
direct costs of HBV infection in Australia to 2017, and investigates the costeffectiveness
of increasing the proportion of people with chronic hepatitis B
(CHB) receiving drug therapy.
| Original language | English |
|---|---|
| Article number | FP-081 |
| Pages (from-to) | 53 |
| Journal | Hepatology International |
| Volume | 4 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Mar 2010 |
| Event | The 20th Conference of the Asian Pacific Association for the Study of the Liver - Beijing China Duration: 1 Jan 2010 → … |